TABLE 2.
The prevalence of new-onset atrial fibrillation (NOAF) and the risk estimate for NOAF based on the Q of stress hyperglycemia ratio (SHR).
| Q | No. of NOAF | OR (95% CI) | P-value | P-trend | |
| NLR | – | – | 1.047 (1.013–1.082) | 0.006 | – |
| SHR | – | – | 3.298 (1.415–7.690) | 0.006 | – |
| NLR | Q1 (n = 801) | 44 (5.5%) | Ref | <0.001 | |
| Q2 (n = 799) | 42 (5.3%) | 0.871 (0.549–1.382) | 0.558 | ||
| Q3 (n = 796) | 54 (6.8%) | 0.941 (0.601–1.474) | 0.791 | ||
| Q4 (n = 798) | 105 (13.2%) | 2.037 (1.341–3.095) | 0.001 | ||
| SHR | Q1 (n = 794) | 52 (6.5%) | Ref | 0.007 | |
| Q2 (n = 808) | 50 (6.2%) | 1.100 (0.717–1.689) | 0.662 | ||
| Q3 (n = 795) | 46 (5.8%) | 0.887 (0.570–1.381) | 0.596 | ||
| Q4 (n = 797) | 97 (12.2%) | 1.733 (1.130–2.657) | 0.012 |
In patients without DM: SHR-Q1, ≤0.74; SHR-Q2, 0.75–0.81; SHR-Q3, 0.82–0.89; SHR-Q4, >0.89; NLR-Q1, ≤2.46; NLR-Q2, 2.47–3.72; NLR-Q3, 3.73–5.93; NLR-Q4, >5.93; in patients with DM: SHR-Q1, ≤0.72; SHR-Q2, 0.73–0.83; SHR-Q3, 0.84–0.97; SHR-Q4, >0.97; NLR-Q1, ≤2.43; NLR-Q2, 2.44–3.46; NLR-Q3, 3.47–5.64; NLR-Q4, >5.64. Adjusted for age, sex, estimated glomerular filtration rate (eGFR), smoking, congestive heart failure (CHF), KILLIP > 1, heart rate (HR) at admission, left ventricular ejection fraction (LVEF), out-of-hospital cardiac arrest (OHCA), glucose, prior myocardial infarction (MI), prior stroke, left atrium diameter (LAD), log-transformed B-type natriuretic peptide (logBNP), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and percutaneous coronary intervention (PCI) treatment.